



Micah Skeens

Principal Investigator, Abigail Wexner Research Institute at Nationwide Children's Hospital, United States

Biography

Micah Skeens, PhD, APRN, FAAN, CPNP-PC, is a distinguished researcher and healthcare professional at the forefront of pediatric oncology and hematopoietic stem cell transplant research and care. Dr. Skeens, who holds a doctorate from Vanderbilt University, is principal investigator in the Center for Biobehavioral Health at the Research Institute at Nationwide Children's Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine and Nursing. She is also a distinguished fellow in the American Academy of Nursing. Dr. Skeens leads the Skeens Lab, where groundbreaking research unfolds at the intersection of psychosocial and biobehavioral outcomes for children facing cancer and undergoing stem cell transplants. She also continues to practice clinically as an advanced practice provider in the Division of Hematology/Oncology/BMT at Nationwide Children's Hospital.

With a passion for innovation, Dr. Skeens is dedicated to developing cutting-edge digital health interventions that address the unique needs of underrepresented and vulnerable populations. Particularly attentive to linguistic diversity and the challenges faced by those in rural and Appalachian regions, Dr. Skeens is committed to ensuring that advancements in pediatric cancer care are inclusive and accessible.

Known for employing mixed methodologies, including qualitative approaches, Dr. Skeens seeks a deeper understanding of the lived experiences of families affected by pediatric cancer and hematopoietic stem cell transplant. Through this comprehensive approach, Dr. Skeens aims to contribute to the scientific understanding of the field and improve the daily lives and outcomes of pediatric cancer patients.

With a blend of expertise in healthcare, research, and compassionate patient care, Dr. Micah Skeens is making significant strides in advancing knowledge and pioneering innovative solutions in the challenging landscape of pediatric oncology.